Paid Clinical Trials for Blood Disorders

Paid Clinical Trials and Focus Groups


Find Paid Clinical Trials

Paid Clinical Trials - : Blood Disorders

Top of Directory » All Categories » by Illness » Blood Disorders



  • Study of Oral Arsenic Trioxide With or Without Ascorbic Acid in Adults With Myelofibrosis

    Condition:   Primary Myelofibrosis
    Intervention:   Drug: Dose Escalating Arsenic Trioxide plus ascorbic Acid
    Sponsors:   Roswell Park Cancer Institute;   Cephalon
    Not yet recruiting - verified November 2009
  • Safety and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of Acute Graft Versus Host Disease (aGVHD) During Transplant

    Conditions:   AML;   ALL;   Undifferentiated Leukemia;   Biphenotypic Leukemia;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ringed Sideroblasts;   Refractory Anemia With Excess Blasts-1 (5-10% Blasts);   Refractory Anemia With Excess Blasts-2 (10-20% Blasts);   Myelodysplastic Syndrome, Unclassified;   MDS Associated With Isolated Del (5q)
    Intervention:   Drug: Abatacept
    Sponsor:   Emory University
    Recruiting - verified November 2009
  • Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

    Conditions:   Stem Cell Transplantation;   Leukemia;   Hematologic Malignancies
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Mesna;   Drug: Rituximab;   Procedure: Stem Cell Transplantation;   Drug: Thiotepa
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified November 2009
  • Red Cell Mass and Plasma Volume Measurements in Elderly Men and Women With Unexplained Anemia

    Condition:   Anemia
    Intervention:  
    Sponsor:   Stanford University
    Recruiting - verified November 2009
  • The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia

    Condition:   Chronic Myelomonocytic Leukemia
    Intervention:  
    Sponsor:   University of Arkansas
    Recruiting - verified November 2009
  • To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.

    Condition:   Myelodysplastic Syndromes
    Interventions:   Drug: decitabine;   Drug: azacitidine
    Sponsor:   Eisai Inc.
    Not yet recruiting - verified November 2009
  • A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)

    Condition:   Chronic Myelogenous Leukemia
    Intervention:   Drug: Gleevec (imatinib), valproic acid
    Sponsor:   New Mexico Cancer Care Alliance
    Recruiting - verified November 2009
  • Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

    Conditions:   Hematopoietic/Lymphoid Cancer;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large-Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   B-cell Chronic Lymphocytic Leukemia;   Burkitt Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Lymphoma, Mucosa-Associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Peripheral T-Cell Lymphoma;   Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Splenic Marginal Zone Lymphoma;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: carmustine;   Drug: etoposide;   Drug: cytarabine;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Radiation: total-body irradiation;   Drug: melphalan;   Procedure: autologous-allogeneic tandem hematopoietic stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Other: fluorescence in situ hybridization;   Other: flow cytometry;   Other: RNA analysis;   Other: laboratory biomarker analysis;   Other: cytogenetic analysis;   Other: polymerase chain reaction
    Sponsor:   Fred Hutchinson Cancer Research Center
    Not yet recruiting - verified November 2009
  • Health-Related Quality of Life (QOL), Physical and Respiratory Function in Patients With Myeloma Affecting the Spine

    Condition:   Multiple Myeloma
    Intervention:   Procedure: kyphoplasty
    Sponsors:   University of California, San Francisco;   Medtronics, Inc.
    Not yet recruiting - verified October 2009
  • Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial

    Condition:   Leukemia
    Interventions:   Genetic: DNA analysis;   Genetic: Southern blotting;   Genetic: cytogenetic analysis;   Genetic: polymerase chain reaction
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia

    Condition:   Severe Thalassemia
    Intervention:   Drug: Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan
    Sponsors:   Washington University School of Medicine;   New England Research Institutes;   Pediatric Blood and Marrow Transplant Consortium
    Not yet recruiting - verified October 2009
  • Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients

    Condition:   Myelodysplastic Syndrome
    Intervention:   Drug: Clofarabine
    Sponsor:   Roswell Park Cancer Institute
    Not yet recruiting - verified October 2009
  • Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

    Condition:   Multiple Myeloma
    Intervention:   Drug: BT062
    Sponsors:   Biotest Pharmaceuticals Corporation;   Biotest
    Not yet recruiting - verified October 2009
  • Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita

    Conditions:   Fanconi Anemia;   Dyskeratosis Congenita
    Intervention:   Drug: danazol
    Sponsor:   Children's Hospital Boston
    Not yet recruiting - verified October 2009
  • Efficacy of Vorinostat to Induce Fetal Hemoglobin in Adults With Severe Sickle Cell Disease Who Have Failed Prior Therapy

    Condition:   Sickle Cell Disease
    Intervention:   Drug: vorinostat
    Sponsors:   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Children's Hospital Boston;   Merck
    Not yet recruiting - verified October 2009
  • Eltrombopag for Post Transplant Thrombocytopenia

    Condition:   Thrombocytopenia
    Interventions:   Drug: Eltrombopag;   Drug: Placebo
    Sponsor:   M.D. Anderson Cancer Center
    Not yet recruiting - verified October 2009
  • Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

    Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group
    Recruiting - verified November 2009
  • Donor Stem Cell Transplant After Total-Body Irradiation in Treating Patients With Relapsed or Refractory Hematologic Cancer or Acute Myeloid Leukemia or Acute Lymphocytic Leukemia in Complete Remission

    Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: cellular immunotherapy;   Biological: donor lymphocytes;   Biological: filgrastim;   Biological: pegfilgrastim;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsors:   Cancer Institute of New Jersey;   National Cancer Institute (NCI)
    Recruiting - verified October 2009
  • Initial Treatment of Patients With Immune Thrombocytopenic Purpura

    Condition:   Immune Thrombocytopenic Purpura
    Interventions:   Drug: Dexamethasone USP Micronized;   Drug: Prednisone
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Not yet recruiting - verified October 2009
  • Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer

    Condition:   Pancreatic Cancer
    Interventions:   Procedure: Endoscopic Ultrasound (EUS);   Device: EUS/4D-ELF
    Sponsor:   Mayo Clinic
    Not yet recruiting - verified November 2009
  • Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390

    Conditions:   Hepatitis C;   Thrombocytopaenia
    Intervention:   Drug: Eltrombopag
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009
  • Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation

    Conditions:   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemias;   Multiple Myeloma With Plasmacytoma
    Interventions:   Procedure: Single fraction radiation (8-Gy);   Procedure: Donor Lymphocyte Infusion
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2009
  • Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients

    Conditions:   Non-dipper;   Nocturnal Hypertension
    Interventions:   Drug: Time change;   Drug: Enalapril, Isradapine, Propranolol
    Sponsors:   North Shore Long Island Jewish Health System;   Children's Hospital of Philadelphia
    Recruiting - verified November 2009
  • Fetal Umbilical Cord Blood (UCB) Transplant for Lysosomal Storage Diseases

    Conditions:   Lysosomal Storage Diseases;   Inborn Errors of Metabolism
    Intervention:   Biological: ALD-601
    Sponsors:   Duke University;   Aldagen
    Recruiting - verified October 2009
  • Study of Blood and Cheek Cell Samples From Patients With Glioma

    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: medical chart review
    Sponsors:   UCSF Helen Diller Family Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment

    Condition:   Chronic Myelogenous Leukemia
    Intervention:   Drug: Nilotinib
    Sponsor:   Novartis Pharmaceuticals
    Not yet recruiting - verified October 2009
  • Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia

    Conditions:   Peripheral Blood Stem Cell Transplantation;   Anemia, Sickle Cell;   Graft-Versus-Host Disease;   Sirolimus (Rapamune(Registered Trademark));   Alemtuzumab (Campath(Registered Trademark))
    Interventions:   Procedure: PBMC Transplant;   Drug: Alemtuzumab (Campath(Registered Trademark));   Drug: Sirolimus (Rapamune(Registered Trademark));   Drug: Cyclophosphamide (Cytoxan(Registered Trademark));   Procedure: Low Dose Irradiation
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified August 2009
  • Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725

    Condition:   Congenital FXIII Deficiency
    Intervention:   Drug: recombinant factor XIII
    Sponsor:   Novo Nordisk
    Recruiting - verified October 2009
  • Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study

    Condition:   Hypertension
    Intervention:   Drug: Lisinopril, Atenolol
    Sponsors:   Brigham and Women's Hospital;   University of Utah
    Recruiting - verified November 2009
  • Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia

    Condition:   Leukemia
    Interventions:   Genetic: fluorescence in situ hybridization;   Genetic: mutation analysis;   Genetic: nucleic acid sequencing;   Genetic: polymerase chain reaction;   Genetic: western blotting;   Other: flow cytometry;   Other: laboratory biomarker analysis
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Effect of Tranexamic Acid in Upper Gastrointestinal Bleeding

    Condition:   Gastrointestinal Bleeding
    Interventions:   Drug: tranexamic acid;   Other: Placebo
    Sponsor:   University of Oklahoma
    Not yet recruiting - verified October 2009
  • Study of Bone Marrow and Blood Samples in Patients With Untreated Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Enrolled on Clinical Trial CALGB-9621 or CALGB-9720

    Condition:   Leukemia
    Intervention:   Other: laboratory biomarker analysis
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Safety and Efficacy of Direct Blood Volume Measurement in the Treatment of Heart Failure

    Condition:   Heart Failure
    Interventions:   Other: Daxor Blood Volume Analysis;   Other: Clinical volume status assessment
    Sponsors:   New York University School of Medicine;   Daxor Corporation
    Not yet recruiting - verified October 2009
  • A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Blood Pressure

    Condition:   Hypertension
    Interventions:   Drug: Acetylsalicylic acid, simvastatin, and ramipril;   Drug: Ramipril
    Sponsor:   Ferrer Internacional S.A.
    Recruiting - verified October 2009
  • Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia

    Condition:   Waldenstrom's Macroglobulinemia
    Intervention:   Drug: RAD001
    Sponsors:   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Novartis
    Recruiting - verified November 2009
  • Effect of Prednisone onTregs and TH17

    Condition:   Chronic Rhinosinusitis
    Intervention:   Drug: prednisone
    Sponsor:   University of Chicago
    Recruiting - verified November 2009
  • Study of Tissue and Blood Samples From Patients With High-Grade Glioma

    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Genetic: DNA ploidy analysis;   Genetic: fluorescence in situ hybridization;   Genetic: microsatellite instability analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Other: diagnostic laboratory biomarker analysis;   Other: flow cytometry;   Other: immunohistochemistry staining method
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Study of Tissue and Blood Samples From Patients With Low-Grade Glioma

    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Genetic: fluorescence in situ hybridization;   Genetic: loss of heterozygosity analysis;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: immunohistochemistry staining method
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Restoring Sleep Homeostasis to Lower Blood Pressure

    Conditions:   Hypertension;   Pre-Hypertension
    Intervention:   Behavioral: Sleep extension
    Sponsor:   Beth Israel Deaconess Medical Center
    Recruiting - verified November 2009
  • Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies

    Conditions:   Kaposiform Hemangioendotheliomas;   Tufted Angioma;   Capillary Venous Lymphatic Malformation;   Venous Lymphatic Malformation;   Microcystic Lymphatic Malformation;   Mucocutaneous Lymphangiomatosis and Thrombocytopenia;   Capillary Lymphatic Arterial Venous Malformations;   PTEN Overgrowth Syndrome With Vascular Anomaly;   Lymphangiectasia Syndromes
    Intervention:   Drug: sirolimus
    Sponsor:   Children's Hospital Medical Center, Cincinnati
    Recruiting - verified October 2009
  • Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies

    Condition:   Healthy
    Intervention:  
    Sponsors:   Center for Human Immunology (CHI);   Center for Human Immunology
    Recruiting - verified August 2009
  • Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma

    Condition:   Lymphoma
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Study of Tissue and Blood Samples in Women With Locally Advanced or Metastatic Breast Cancer Undergoing Chemotherapy Before Surgery

    Condition:   Breast Cancer
    Interventions:   Other: biologic sample preservation procedure;   Other: flow cytometry;   Other: immunohistochemistry staining method;   Procedure: biopsy
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified October 2009
  • A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis

    Conditions:   Anemia;   Chronic Kidney Disease
    Interventions:   Drug: MK2578;   Drug: Comparator: MK2578;   Drug: Comparator: MK2578;   Drug: Comparator: darbepoetin alfa
    Sponsor:   Merck
    Recruiting - verified November 2009
  • A Brief Study To Evalute The Safety, Tolerabiltiy, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease

    Condition:   Alzheimer's Disease
    Interventions:   Drug: PF-04447943;   Drug: Placebo
    Sponsor:   Pfizer
    Not yet recruiting - verified October 2009
  • Safety and Tolerability of TAK-491 Plus Chlorthalidone Compared to Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Essential Hypertension

    Condition:   Essential Hypertension
    Interventions:   Drug: TAK-491 and chlorthalidone;   Drug: Olmesartan medoxomil-hydrochlorothiazide
    Sponsor:   Takeda Global Research & Development Center, Inc.
    Recruiting - verified November 2009
  • A Phase 1/2 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia

    Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Blast-phase Chronic Myelogenous Leukemia;   AML;   ALL;   CML
    Intervention:   Drug: STA-9090
    Sponsor:   Synta Pharmaceuticals, Corp.
    Recruiting - verified November 2009
  • Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels

    Condition:   HIV Infections
    Intervention:   Drug: maraviroc (Selzentry)
    Sponsors:   University of Hawaii;   Pfizer Pharmaceutical
    Not yet recruiting - verified September 2009
  • Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral MLN9708 in Adult Patients With Relapsed and Refractory Multiple Myeloma

    Condition:   Relapsed and Refractory Multiple Myeloma
    Intervention:   Drug: Oral MLN9708
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting - verified November 2009
  • Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

    Conditions:   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Drug: everolimus;   Drug: panobinostat;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
    Recruiting - verified August 2009
    • Menu
    Find Paid Clinical Trials